BETA
Your AI-Trained Oncology Knowledge Connection!
Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC
Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.
NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer
The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.
Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC
A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.
Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.
Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC
Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.
FDA ODAC Votes 5-to-4 Against UGN-102 Intravesical Solution for Bladder Cancer
ODAC has voted against the use of UGN-102 intravesical solution for patients with advanced bladder cancer.